Complete response letter is issued by USFDA to new drug / abbreviated application holder, if they determines that we will not approve the application or abbreviated application in its present form for one or more of the reasons.
- Description of specific deficiencies.
- Complete review of data.
- In case of Inadequate data, they highlights inadequacy.
- They also mention recommended action for approval.